Xiantong Pharmaceutical-B (09941) proposed to sell 6.561 million H shares globally from November 16 to November 19

Zhitongcaijing · 1d ago

According to the Zhitong Finance App, Xiantong Pharmaceutical-B (09941) will raise shares from November 16 to November 19, 2026. The company plans to sell 6.561 million H shares globally, of which Hong Kong sales account for 10% and international sales account for 90%. The sale price will be HK$52.0 to HK$68.0 per share, 50 shares per lot. It is expected that the shares will start trading on the Stock Exchange on November 24, 2026.

The company is committed to developing and commercializing diagnostic and therapeutic radiopharmaceuticals with considerable market potential. The company was founded in 2005. As of the last practical date, a phased, indication-oriented development pipeline has been established, including 13 assets, 5 of which were independently discovered and developed by the company, and 3 were independently developed by the company. The company's pipeline includes two core products, XTR008 and XTR004, and two main products, XTR003 and XTR006. Xtr008 is a radioligand of 177Lu-labeled targeting somatostatin receptor (SSTR) in the registration stage for the treatment of neuroendocrine tumors (NEN). It is a generic of Lutathera®, and it is the first of its kind to submit an NDA to the National Drug Administration using 3 types of chemicals. It is expected to be approved for marketing in December 2026.

For the years ended 2024 and 31 December 2025, and for the six months ended 2025 and June 30, 2026, the company recorded revenue of RMB 44.1 million, RMB 99.2 million, RMB 36.9 million and RMB 61.3 million respectively. The company recorded net losses of RMB 156 million, RMB 618 million, RMB 328 million and RMB 534 million respectively for the year ended 2024 and 31 December 2025 and the six months ended June 30, 2026.

Assuming that the over-allotment rights are not exercised and that the offering price is HK$60.0 per share (the median of the indicative offer price range as described in this prospectus), after deducting underwriting commissions, fees and other estimated expenses paid and payable in connection with the global offering, the company estimates that the net proceeds from the global offering will be approximately HK$329 million. If the offering price were determined to be HK$52.0 per share (the lower limit of the indicative offer price range), the net proceeds from the global offering would be reduced by approximately HK$50.4 million. If the offering price were determined to be HK$68.0 per share (the upper limit of the indicative offer price range), the net proceeds from the global offering would increase by approximately HK$50.4 million.

Assuming that the sale price is the median of the indicative sale price range, and the over-allotment rights are not exercised, the company plans to use the net proceeds from the global sale for the following purposes: 88.0% will be used for the development and registration of core products; 4.9% will be used to develop the company's other candidate products; 1.1% will be used to strengthen the company's sales and marketing capabilities; 1.1% will be used to build a new production base in Tianjin; and 5.0% will be used for working capital and other general corporate purposes.